Keen, Nicholas

High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response

Gao, H., Korn, J. M., Ferretti, S., Monahan, J. E., Wang, Y., Singh, M., Zhang, C., Schnell, C., Yang, G., Zhang, Y., et al. (2015) · Nature Medicine

Cancer Cells and MetastasisCancer Genomics and Diagnostics

Cited by 1,393

Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases

Chen, Y.-N. P., LaMarche, M. J., Chan, H. M., Fekkes, P., Garcia-Fortanet, J., Acker, M. G., Antonakos, B., Chen, C. H.-T., Chen, Z., Cooke, V. G., et al. (2016) · Nature

Protein Tyrosine PhosphatasesProtein Kinase Regulation and GTPase Signaling

Cited by 925

Project DRIVE: a compendium of cancer dependencies and synthetic lethal relationships uncovered by large-scale, deep RNAi screening

McDonald, E. R., de Weck, A., Schlabach, M. R., Billy, E., Mavrakis, K. J., Hoffman, G. R., Belur, D., Castelletti, D., Frias, E., Gampa, K., et al. (2017) · Cell

Chromatin Remodeling and CancerCancer Genomics and Diagnostics

Cited by 658

Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5

Mavrakis, K. J., McDonald, E. R., Schlabach, M. R., Billy, E., Hoffman, G. R., deWeck, A., Ruddy, D. A., Venkatesan, K., Yu, J., McAllister, G., et al. (2016) · Science

Cancer-related gene regulationRNA modifications and cancer

Cited by 607

Studying clonal dynamics in response to cancer therapy using high-complexity barcoding

Bhang, H.-E. C., Ruddy, D. A., Krishnamurthy Radhakrishna, V., Caushi, J. X., Zhao, R., Hims, M. M., Singh, A. P., Kao, I., Rakiec, D., Shaw, P., et al. (2015) · Nature Medicine

Cancer Genomics and DiagnosticsSingle-cell and spatial transcriptomics

Cited by 507

Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers

Hoffman, G. R., Rahal, R., Buxton, F., Xiang, K., McAllister, G., Frias, E., Bagdasarian, L., Huber, J., Lindeman, A., Chen, D., et al. (2014) · Proceedings of the National Academy of Sciences

Chromatin Remodeling and CancerEpigenetics and DNA Methylation

Cited by 421

Structural Basis of Substrate Methylation and Inhibition of SMYD2

Ferguson, A. D., Larsen, N. A., Howard, T., Pollard, H., Green, I., Grande, C., Cheung, T., Garcia-Arenas, R., Cowen, S., Wu, J., et al. (2011) · Structure

Cancer-related gene regulationEpigenetics and DNA Methylation

Cited by 203

Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors

Gibaja, V, Shen, F., Harari, J., Korn, J., Ruddy, D., Saenz-Vash, V, Zhai, H., Rejtar, T., Paris, C. G., Yu, Z., et al. (2016) · Oncogene

Epigenetics and DNA MethylationChromatin Remodeling and Cancer

Cited by 149

Abstract PR02: LEE011: An orally bioavailable, selective small molecule inhibitor of CDK4/6– Reactivating Rb in cancer.

Kim, S., Loo, A., Chopra, R., Caponigro, G., Huang, A., Vora, S., Parasuraman, S., Howard, S., Keen, N., Sellers, W., et al. (2013) · Molecular Cancer Therapeutics

Advanced Breast Cancer TherapiesCancer-related Molecular Pathways

Cited by 106

Transfer of Tat and release of TAR RNA during the activation of the human immunodeficiency virus type-1 transcription elongation complex

Keen, N. J., Churcher, M. J., & Karn, J. (1997) · The EMBO Journal

HIV Research and TreatmentGenomics and Chromatin Dynamics

Cited by 59